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Background: Multi-drug resistance (MDR) in Gram-negative organisms is an alarming problem in the world. MDR
and extensively-drug resistance (XDR) is in increasing trend due to the production of different types of beta
(β)-lactamases. Thus the aim of this study was to document the incidence of MDR and XDR in clinical isolates of
Escherichia coli and also to find out the enzymatic mechanisms of β-lactam antibiotics resistance.
Methods: Two hundred clinical isolates of Escherichia coli (E. coli) identified by standard laboratory methods were
studied. Antibiotic susceptibility profile was performed for all the isolates and the suspected isolates were phenotypically
tested for the production of extended spectrum β-lactamase (ESBL), metallo β-lactamase (MBL) and AmpC β-lactamase
(AmpC) by recommended methods.
Results: Around three-fourth (78%) of the total isolates were multi-drug resistant. ESBL, MBL and AmpC production was
found in 24%, 15% and 9% of isolates respectively. Amikacin, chloramphenicol and colistin were found to be the most
effective antibiotics.
Conclusions: High percentage of MDR was observed. β-lactamase mediated resistance was also high. Thus, regular
surveillance of drug resistance due to β-lactamases production and infection control policy are of utmost importance to
minimize the spread of resistant strains.
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Resistance to broad spectrum β-lactams, mediated by ex-
tended spectrum β-lactamases (ESBL), metallo β-lactamases
(MBL) and AmpC β-lactamases (AmpC) enzymes is an in-
creasing problem worldwide [1]. Presence of the latter two
enzymes in clinical infections can result in treatment failure
if one of the second- or third-generation cephalosporin is
used. The scenario worsens in cases of MBL production
where the drugs of last resort the carbapenems are rendered
inactive [2]. Due to extensive use of β-lactam antibiotics
over the last several decades in the clinical practice, various
β-lactamases have emerged. ESBLs are the enzymes pro-
duced by Gram-negative bacilli that have the ability to* Correspondence: shamshulansari483@yahoo.com
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unless otherwise stated.hydrolyze β-lactam antibiotics containing an oxyimino
group (third generation cephalosporins and aztreonam) and
are inhibited by β-lactamase inhibitors such as clavulanic
acid, sulbactam and tazobactam [3].
ESBLs were first identified in 1983. Since the time, they
have been found worldwide in a number of organisms, in-
cluding Klebsiella pneumoniae (K. pneumoniae), Klebsiella
oxytoca, Escherichia coli (E. coli), Proteus mirabilis, Entero-
bacter cloacae, Morganella morganii, Serratia marcescens,
Shigella dysenteriae, Pseudomonas aeruginosa, Burkholderia
cepacia, Capnocytophaga ochracea, Citrobacter species, and
Salmonella species [4-10].
The emergence of ESBL producing bacteria, particu-
larly E. coli and K. pneumoniae, is now a critical concern
for the development of therapies against bacterial infec-
tion. The major ESBL producer was K. pneumoniae be-
fore 2000, but now E. coli has become an importantThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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genes are usually found in large plasmids, they also con-
tain other antimicrobial resistant genes. Therefore, most
ESBL producing organisms are also resistant to aminogyl-
cosides, fluororquinolones, tetracyclines, chloramphenicol,
sulfonamides. Carbapenems are the mainstay of therapy
for infections caused by ESBL producing organisms [14].
Therefore, resistance against these agents poses thera-
peutic challenge. Based on molecular studies, carbapenem
hydrolyzing enzymes are classified into four groups A, B,
C and D. The MBLs belong to group B and are enzymes
requiring divalent cations as cofactors for enzyme activity,
being inhibited by the action of a metal ion chelator [15].
The MBLs efficiently hydrolyze all β-lactams, except aztre-
onam in vitro [16].
AmpC-mediated β-lactam resistance in E. coli and Kleb-
siella spp. is an emerging problem [17]. High level AmpC
production is typically associated with in vitro resistance
to all β-lactam antibiotics except for carbapenems and
cefepime. In addition, treatment failures with broad-
spectrum cephalosporins have been documented [18,19].
The production of β-lactamases is the single most preva-
lent mechanism responsible for resistance to β-lactams
among clinical isolates belonging to the family of Entrobac-
teriaceae [20]. Over the years, many new β-lactam antibi-
otics have been developed. However, with each new class of
antibiotics, a new β-lactamase has emerged and caused re-
sistance to it. Presumably, the selective pressure imposed
by the use and overuse of new antibiotics in the treatment
of patients has resulted in the emergence of new variants of
β-lactamases [21]. In this perspective, the present study was
designed to document the existence of ESBL, MBL and
AmpC-production in clinical isolates of multi-drug and
extensively-drug resistant E. coli and to determine whether
any alternative regimens are available to treat them.
Methods
A total of 200 random, non-redundant and non-repetitive
community acquired clinical isolates of E. coli (urine 90,
sputum 50, pus 40, blood 20), identified by standard
microbiological technique [22] in the bacteriological la-
boratory of Chitwan Medical College Teaching Hospital
(CMCTH), a 600 bed tertiary care center of central Nepal
in 2013, were subjected to phenotypic determination of
the antimicrobial susceptibility, identification of MDR,
XDR and pan drug resistant (PDR); and detection of
ESBL, MBL and AmpC β-lactamase production.
Antimicrobial susceptibility testing
Antibiograms of the isolates were determined by modi-
fied Kirby-Bauer disk diffusion method on Mueller-
Hinton agar standard media using commercially prepared
disks (HiMedia Laboratories Pvt. Limited, India) in com-
pliance with Clinical and Laboratory Standards Institute(CLSI) guidelines [23]. Antimicrobials used were: penicillin
[ampicillin (10 μg)], penicillins with β-lactamase inhibitors
[ampicillin-sulbactam (10/10 μg), amoxicillin-clavulanic
acid (10 μg)], narrow spectrum cephalosporin [cefazolin
(30 μg)], extended spectrum cephalosporins [ceftazidime
(30 μg), ceftriaxone (30 μg), cefepime (30 μg)], cephamycin
[cefoxitin (30 μg)], antipseudomonal penicillins with
β-lactamase inhibitors [piperacillin-tazobactam (100/10 μg),
ticarcillin-clavulanic acid (75/10 μg)], monobactam [aztreo-
nam (30 μg)], carbapenems [imipenem (10 μg), meropenem
(10 μg)], aminoglycosides [gentamicin (10 μg), amikacin
(30 μg), tobramycin (10 μg)], fluoroquinolones [ciprofloxa-
cin (5 μg), ofloxacin (5 μg)], folate pathway inhibitor [co-tri-
moxazole (25 μg)], phenicol [chloramphenicol (30 μg)] and
polymyxin [colistin (10 μg)]. Interpretation of susceptibility
was made according to the tables for interpretative zone di-
ameters of CLSI [23]. E. coli 25922 was used as a control
organism for antibiotic sensitivity testing.
Identification of MDR, XDR and PDR isolates
MDR, XDR and PDR isolates were identified according
to the guidelines recommended by joint initiative of the
European Centre for Disease Prevention and Control
(ECDC) and the Centers for Disease Control and Pre-
vention (CDC) [24]. According to the guidelines, the iso-
lates showing non-susceptibility to at least one agent in
three or more antimicrobial categories were identified as
MDR, non-susceptibility to at least one agent in all but
two or fewer antimicrobial categories (i.e. bacterial iso-
lates remained susceptible to only one or two categories)
were identified as XDR and non-susceptibility to all
agents in all antimicrobial categories were identified as
PDR. To ensure correct application of these definitions,
bacterial isolates were tested against all or nearly all of
the commercially available antimicrobial agents within
the antimicrobial categories (recommended by ECDC
and CDC) and selective reporting and suppression of re-
sults were avoided [24].
Phenotypic detection of ESBL
Isolates of E. coli were examined for their susceptibility
to 3rd generation cephalosporins by using ceftazidime
(30 μg) and cefotaxime (30 μg) disks. The isolates show-
ing diameter of ≤ 22 mm zone of inhibition for ceftazi-
dime and/or ≤ 27 mm for cefotaxime were considered as
ESBLs suspects as per National Committee for Clinical
Laboratory Standards (NCCLS) guidelines [25]. All sus-
pected isolates for ESBLs production were confirmed by
the combination disk method on Mueller Hinton agar
plates that were inoculated with standardized inoculums
(comparable to 0.5 McFarland standards) of the isolates
to form a lawn culture. Separate commercial disks con-
taining cefotaxime (30 μg) and ceftazidime (30 μg) with
and without clavulanic acid (10 μg) were placed over the
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equal to 5 mm for cefotaxime and ceftazidime with and
without clavulanic acid indicated ESBL production as
described by Carter et al. [26].
Phenotypic detection of MBL
Isolates that were found resistant to imipenem, merope-
nem or third generation cephalosporins (ceftazidime) in
Kirby Bauer disk diffusion method were presumptively
considered MBL producers and were confirmed
by the imipenem disk with EDTA methods. Briefly, the
test inoculums (comparable to 0.5 McFarland standards)
were prepared and transferred on to Mueller Hinton
agar plates. Two imipenem (10ug) disks were placed on
the surface of agar plate and 10 μl EDTA solutions was
added to one of them to obtain a desired concentration
of 750 μg. Plates were incubated for 16 to 18 hours at
35°C. An increase in zone size of more than or equal to
7 mm for imipenem-EDTA disk compared to imipenem
disk alone indicated MBL producer strain as described
by Yong et al. [27].
Phenotypic detection of AmpC
All E. coli isolates resistant to cefoxitin in Kirby-Bauer disk
diffusion method were confirmed for AmpC β-lactamase
production by modified Hodge test. In the test, a cefoxitin
susceptible E. coli indicator strain (ATCC 25922) was
plated on Muller Hinton agar medium and the cefoxitin
disk was placed. Test organism was streaked toward the
cefoxitin disk. If the test organism expressed AmpC, it hy-
drolyzed the cefoxitin and showed growth along the inter-
section of the streak and the zone of inhibition from the
cefoxitin disk [28].
Ethical consideration
The samples used in this study were from routine clin-
ical specimens; however, verbal consent was taken from
the patients. The ethical approval was obtained from In-
stitutional Review Committee of Chitwan Medical Col-
lege Teaching Hospital (CMCTH), Bharatpur, Nepal to
conduct the study.
Results
Resistance pattern of E. coli
All of the E. coli isolates tested exhibited resistance to
amoxicillin-clavulanic acid and 77 % of them remained
resistant to ciprofloxacin whereas all the isolates were
susceptible to colistin and few isolates (7%) were resist-
ant to imipenem (Table 1).
MDR and XDR isolate
Of total 200 E. coli isolates tested, 156 (78%) isolates
were MDR and 14 (7%) isolates were XDR whereas no
PDR isolate was identified (Table 1).All MDR isolates were resistant to amoxicillin-clavulanic
acid and 91% isolates were resistant to ciprofloxacin
whereas amikacin, imipenem and colistin were found as
the most effective antibiotics for the MDR isolates. All
XDR isolates were resistant to most of the antibiotics
tested whereas colistin was found as the effective regimen
against all XDR isolates (Table 1).
ESBL, MBL and AmpC producing isolates and their
resistance profile
Among total tested isolates, the synthesis of ESBL, MBL
and AmpC was detected in 48 (24%), 30 (15%) and 18 (9%)
isolates respectively (Tables 2 and 3). Most of the antibi-
otics tested were non-effective against ESBL, MBL and
AmpC producers whereas imipenem, amikacin, chloram-
phenicol and colistin were found effective regimens against
ESBL producers and only colistin was effective against
MBL and Amp C producing isolates (Table 2).
Multi-type β-lactamase production
Of the tested isolates, 10 (5%) were producers of both ESBL
and MBL, 8 (4%) isolates synthesized both ESBL and
AmpC whereas 6 (3%) isolates produced both MBL and
Amp C. All the three types of β-lactamases (i.e. ESBL, MBL
and AmpC) were detected in 4 (2%) isolates (Table 3).
Resistance rates of antibiotics with different mode of
action
All of the tested isolates were resistant to at least one cell
wall inhibiting agents followed by folic acid metabolism
inhibiting agent (59%) whereas no isolates were resistant
to cytoplasmic membrane damaging agent (Table 4).
Incidence of resistant isolates
Very minor numbers of isolates (4%) were resistant to
only one antibiotic whereas majorities (85%) of isolates
were resistant to at least three antibiotics (Table 5).
Discussions
The production of β-lactamases as a major problem have
drawn attention to a need for better diagnostic tech-
niques and newer drugs to allow more specific therapy
because of the emergence and spread of antimicrobial
resistance. Therefore, the detection, characterization and
antibiotic susceptibility pattern of β-lactamase producing
organisms can lead to successful infection control, in-
volving antimicrobial stewardship and public health in-
terventions aimed at controlling the emergence of such
life-threatening MDR bacteria. The global rise of MDR
organisms and their production of resistant enzymes is a
serious public health threat now a day.
There are various documented literatures on investiga-
tion of ESBL, MBL and AmpC producing isolates from
Nepal. To the best of our knowledge, this is the first
Table 1 Resistance rates of E. coli
Antibiotics No. of resistant
isolates (%)






Ampicillin 148 (74) 130 (83.3) 14 (100.0)
Penicillins with β-lactamase inhibitors
Ampicillin-sulbactam 114 (57) 100 (64.1) 14 (100.0)
Narrow spectrum cephalosporins
Cefazolin 142 (71) 122 (78.2) 14 (100.0)
Extended spectrum cephalosporins
Ceftazidime 104 (52) 84 (53.8) 14 (100.0)
Ceftriaxone 82 (41) 68 (43.6) 14 (100.0)
Cefepime 62 (31) 68 (43.6) 14 (100.0)
Cephamycins
Cefoxitin 82 (41) 66 (42.3) 14 (100.0)
Antipseudomonal penicillins with β-lactamase inhibitors
Piperacillin-tazobactam 48 (24) 34 (21.8) 14 (100.0)
Ticarcillin-clavulanic acid 114 (57) 100 (64.1) 14 (100.0)
Amoxicillin-clavulanic acid 200 (100) 156 (100.0) 14 (100.0)
Monobactams
Aztreonam 72 (36) 58 (37.2) 14 (100.0)
Carbapenems
Imipenem 14 (7) 0 (0) 14 (100.0)
Meropenem 74 (37) 60 (38.5) 14 (100.0)
Aminoglycosides
Gentamicin 40 (20) 26 (16.7) 14 (100.0)
Amikacin 20 (10) 6 (3.8) 14 (100.0)
Tobramycin 44 (22) 32 (20.5) 12 (85.7)
Fluoroquinolones
Ciprofloxacin 154 (77) 142 (91.0) 14 (100.0)
Ofloxacin 94 (47) 78 (25.0) 14 (100.0)
Folate pathway inhibitors
Cotrimoxazole 118 (59) 102 (65.4) 14 (100.0)
Phenicols
Chloramphenicol 34 (17) 20 (12.8) 12 (85.7%)
Polymyxins
Colistin 0 (0) 0 (0) 0 (0)
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the current incidence and antimicrobial susceptibility pat-
terns to a large number of antibiotics tested among ESBL,
MBL and AmpC producing MDR and XDR E. coli isolates.
In current study we investigated 200 clinical isolates
of E. coli, all of which were resistant to amoxicillin-
clavulanic acid and 77 % of the isolates were found re-
sistant to ciprofloxacin. Our finding is similar to theobservation of Khanal et al. who reported that 66.7% of
isolates were resistant to ciprofloxacin [29]. However,
Khadgi et al. reported 100% resistance to ciprofloxacin
[30]. Among the antimicrobials tested, colistin (100%),
imipenem (93%) and amikacin (90%) were found as the
most effective agents against E. coli in our study. Poly-
myxin (colistin) and amikacin as the most effective anti-
biotics has also been defined by other authors and it can
Table 2 Resistance pattern of ESBL, MBL and AmpC producing isolates







Ampicillin 44 (91.7) 24 (80.0) 18 (100)
Ampicillin-sulbactam 44 (91.7) 24 (80.0) 18 (100)
Cefazolin 48 (100) 28 (93.3) 16 (88.9)
Ceftazidime 48 (100) 30 (100) 18 (100)
Ceftriaxone 48 (100) 24 (80.0) 12 (66.7)
Cefepime 36 (75.0) 16 (53.3) 0 (0)
Cefoxitin 34 (70.8) 26 (86.7) 18 (100)
Piperacillin-tazobactam 22 (45.8) 18 (60.0) 12 (66.7)
Ticarcillin-clavulanic acid 44 (91.7) 22 (73.3) 16 (88.9)
Amoxicillin-clavulanic acid 48 (100) 30 (80.0) 18 (100)
Aztreonam 48 (100) 22 (73.3) 12 (66.7)
Imipenem 2 (4.2) 14 (46.7) 4 (22.2)
Meropenem 32 (66.7) 22 (73.3) 12 (66.7)
Gentamicin 14 (29.2) 18 (60.0) 6 (33.3)
Amikacin 2 (4.2) 16 (53.3) 4 (22.2)
Tobramicin 16 (33.3) 16 (53.3) 6 (33.3)
Ciprofloxacin 46 (95.8) 28 (93.3) 18 (100)
Ofloxacin 40 (83.3) 24 (80.0) 14 (77.8)
Cotrimoxazole 40 (83.3) 24 (80.0) 12 (66.7)
Chloramphenicol 6 (12.5) 14 (46.7) 4 (22.2)
Colistin 0 (0) 0 (0) 0 (0)
Ansari et al. Antimicrobial Resistance and Infection Control  (2015) 4:15 Page 5 of 8be concluded that amikacin is a promising regimen for
the empirical therapy [29-31]. Chloramphenicol is still
an effective drug after so many years in use as only small
percentage of isolates (17%) were resistant to it, a drug
approved in 1947 for human clinical use.
In present study, of total isolates tested, 156 (78%) iso-
lates were MDR. Similarly, higher rate of MDR was also
reported by Sharma et al. (90.8%) [32] whereas Khanal
et al. (50%) [29] and Baral et al. (38.2%) [31] reported its
lower rate from Nepal. A high incidence of MDR E. coliTable 3 Type of β-lactamases production among E.coli
isolates
Type of β-lactamases No. of producing isolates (%)
ESBL 48 (24)
MBL 30 (15)
Amp C 18 (9)
ESBL +MBL 10 (5)
ESBL + Amp C 8 (4)
MBL + Amp C 6 (3)
ESBL +MBL + Amp C 4 (2)was also observed by Ibrahim et al. (92.2%) from Sudan
[33]. As it was a big concern for us, 7% of isolates exhib-
ited XDR in the present study. However, we did not find
any previous literature reporting XDR E. coli in Nepal.
All MDR isolates in this study were resistant to
amoxicillin-clavulanic acid. Resistance to fluoroquino-
lones varies geographically and is an emerging problem
in both developed and developing countries [34,35]. In
the present study, MDR E. coli isolates showed relatively
high resistance rates to ciprofloxacin (91%). This has
been hypothesized to be related to the inappropriate use
(over-use and miss-use) of fluoroquinolones for humans
[36]. Also, prolonged use of low dose of the more potent
fluoroquinolones such as ciprofloxacin has been shown
to be the most significant risk factor for acquisition
of resistance [37]. Majority of the MDR isolates were
resistant to ampicillin (78%) and cotrimoxazole (65.4%).
A few isolates also showed resistance to other antibiotics
such as amikacin (3.8) and chloramphenicol (12.8) and
no isolates were found to be resistant to imipenem and
colistin. Likewise, Baral et al. from Nepal also reported
similar resistance rates of ciprofloxacin (92.6%), ampicil-
lin (94.1%), cotrimoxazole (86.8%), amikacin (6.2%)
Table 4 Resistance profile of isolates tested against 6 major classes of antibiotics with different mode of action
Mode of action Antibiotic classes No. of isolates resistant to at least
one agent of antibiotic classes (%)
Inhibition of cell wall synthesis Beta-lactams 200 (100)
Inhibition of protein synthesis Aminoglycosides 56 (28)
Inhibition of DNA replication Fluoroquinolones 82 (41)
Chloramphenicol 34 (17)
Inhibition of folic acid metabolism Cotrimoxazole 118(59)
Damaging of cytoplasmic membrane Polymyxins (colistin) 0 (0)
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resistant to most of the antimicrobials tested whereas co-
listin was found as the most effective agent against all the
XDR isolates.
ESBL-producing E. coli have been described in hospi-
tals to cause various outbreaks, but their presence in
community has also been documented [38-40]. The re-
duced susceptibility of Gram-negative isolates to the
later generation cephalosporins could be attributable to
ESBL or AmpC β-lactamase production or some other
relevant underlying mechanisms. In this study, 48 (24%)
ESBL and 18 (9%) AmpC β-lactamase producing E. coli
strains were detected. Higher prevalence of ESBL produ-
cing E. coli has also been reported by other authors
[31,41,42] but a lower prevalence of ESBL (8.6%) and
similar prevalence of AmpC (7.8%) has been reported by
Khanal et al. in Nepal [29]. This lower prevalence of
ESBL by Khanal et al. may be due to the selection of
only tracheal isolates from ICU. A higher prevalence of
ESBL (67%) and AmpC (33%) has been reported by Al-
tun et al. from Turkey [43]. This higher prevalence of
ESBL and AmpC by Altun et al. may be because of the
selection of various types of clinical samples from the
ICU patients. MBL production is also in increasing trend
causing the carbapenems to be the ineffective regimens.
In our study we found, 30 (15%) MBL producers among
tested isolates. Our finding is similar to 13.4% docu-
mented by Wadekar et al. from India [42].
Susceptibility pattern of ESBL-producing isolates showed
that these strains are not only resistant to β-lactams but
also to other classes of antibacterials including gentamicin,
cotrimoxazole and fluoroquinolones. In this study, we
found that the β-lactamases producing isolates wereTable 5 Incidence of isolates resistant to antibiotics
Resistant profile No. of isolates (%)
Resistant to only one antibiotic 8 (4)
Resistant to 2 antibiotics 22 (11)
Resistant to 3–20 antibiotics 170 (85)
Total 200 (100)resistant to most of the antibiotics tested but amikacin,
imipenem, chloramphenicol and colistin showed promising
efficacy against ESBL and AmpC producing isolates, which
is in accordance with the other report from Nepal [41].
The carbapenem group of antibiotics is the most effective
regimen for ESBL and AmpC producers but the increasing
rate of MBL production makes the serious problem in in-
fection treatment. We observed that more than half of the
MBL producers were resistant to nearly all the antibiotics
tested while colistin was found effective against all the
MBL producing isolates.
Multi type β-lactamases producing isolates were also re-
ported in our study. Among total tested isolates, 10 (5%)
isolates were producers of both ESBL and MBL. ESBL to-
gether with AmpC production was seen in 8 (4%) isolates,
whereas, 6 (3%) isolates produced both MBL and AmpC
and 4 (2%) isolates did all, ESBL, MBL and AmpC. Similar
result of ESBL with AmpC production (5.4%) was also
documented by Kaur et al. from India [44].
Over the past 20 years there has been increased resist-
ance to β-lactam antibiotics due to production of ESBL
mediated by plasmids. This type of resistance is now ob-
served in all species of Enterobacteriaceae and currently
disseminated worldwide [45]. In this study, no isolates
were documented resistant to cytoplasmic membrane
damaging agents (colistin) whereas all isolates were
found resistant to at least one cell wall inhibiting agents
(β-lactams) and provided a significant contribution for
MDR. In addition, isolates resistant to protein synthesis
inhibiting agents and DNA replication inhibiting agents
seem to have contributed considerably in the production
of MDR. Similar contribution of different antimicrobial
agents was also noticed by Aly et al. in Egypt [46].
In the present study, we found that all the isolates
were resistant to at least one agent and 170 (85%) iso-
lates were resistant to at least 3 agents while 22 (11%)
isolates were resistant to two agents and 8 (4%) isolates
were resistant to only one antimicrobial agent.
Conclusions
This study concluded that, there is high prevalence of
community acquired MDR E. coli and high rate of ESBL,
Ansari et al. Antimicrobial Resistance and Infection Control  (2015) 4:15 Page 7 of 8MBL and AmpC β-lactamase production in our set
up. A strict hospital infection control policies and a pru-
dent use of antimicrobial regimens are to be adopted
by the concerned people to minimize the development
of resistant strains. It is also essential to have a regular
and routine monitoring of ESBL, MBL and AmpC
β-lactamase producing clinical isolates in clinical labora-
tories. Regular nation wise surveillance of multidrug re-
sistance seems necessary step to combat the severity of
infections caused by MDR pathogens. Further studies at
molecular level may be beneficial to rule out the cause
of MDR pattern.
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